BIO Asia–Taiwan 2023 亞洲生技大會

Canada - Taiwan Life Science Forum: Digital and Precision Health, Infection Control

Synopsis:

Canada’s life sciences industry has more than 1000 companies with $2.4 Billion+ R&D and $87.4 Billion revenues. Canada has strong strengths as an emerging leader in health AI, precision medicine, regenerative medicine, genomics & oncology, and also embraces other emerging trends of artificial intelligence, digital health, gene editing and infection control. Canada, as the 8th largest medical device market and 9th largest pharmaceutical market, has 40 world class research hospitals, 17 life science networks/excellence centers, 800 drug products in the pipeline and 60+ incubators & accelerators supporting the life science industry development.

Canadian Trade Office in Taipei (CTOT) co-organizes with Taiwan Bio Industries Organisation (TBIO), Alberta Taiwan Office and British Columbia Taiwan Office on this Canada-Taiwan Life Science Forum during 2023 Bio Asia Taiwan week. Four Canadian companies and organisation with cutting-edge and innovation technology will be introduced to you in the post-COVID era!

Date / Time:Wednesday, July 26, 2023 ｜ 13:30–17:00 pm (Taipei Time)

Venue:Room 702, 7F, TaiNEX 2 / 南港展覽館2館7樓702室 (Address: No.2, Jingmao 2nd Rd., Nangang District, Taipei City 11568, Taiwan /地址: 115台北市南港區經貿二路2號)

Organizer: Canadian Trade Office in Taipei 加拿大駐台北貿易辦事處

Co-organizer: Taiwan Bio Industries Organization, Alberta Taiwan Office

Language: English

Registration: https://reurl.cc/8jb117

此為免費研討會，由於座位有限，主辦單位保有確認報名的權益，敬請見諒。
會中將提供與會者簡便茶點。

Agenda

13:30 – 14:00	Registration
14:00 – 14:05	Opening Remarks Mr. Ed Jager, Director, Canadian Trade Office in Taipei (CTOT)
14:06 – 14:10	Opening Remarks Dr. Herb Wu, Chairman, Taiwan Bio Industries Organisation (TBIO)
14:10 – 14:40	Keynote Speaker Dr. Yi-Yu Ke, Group Director, Institute for Drug Evaluation Platform Digital Health Group, Development Center for Biotechnology Presentation AI-aided Drug Design and Drug Development
14:40 – 15:10	Canadian Speaker Dr. Anmol Kapoor, CEO and Founder BioAro Inc. Presentation Disrupting Healthcare with Precision Health
15:10 – 15:40	Canadian Speaker Larry Mackinnon, Director, Business Development London Economic Development Corporation (LEDC) Presentation Life sciences and medical research excellences at Western University and city of London (tentative)
15:40 – 16:10	Canadian Speaker Ajay Jain, Chief Business Development Officer SteriPro
15:40 – 16:40	Canadian Speaker Dr. Aaron Fenster, Professor and Director, Imaging Labs, Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University Canada Presentation 3D ultrasound system and applications in disease diagnosis and treatment (tentative)
16:40 – 17:00	Q&A and Networking
17:00	End

Japanese Companies: Your Promising Partners

Synopsis:

Japan has one of the most active biotechnology industries in the world, as evidenced by the large number of patent applications. Every day, many pharmaceutical, chemical, healthcare and food companies, from startups to large corporations, are applying various kinds of biotechnologies to their R&Ds to develop novel products.

As seen in the examples of pharmaceutical development, it has increasingly become difficult for a single company to develop products by itself in recent years, leading to the increases in the opportunities for external collaboration in the areas of R&D and manufacturing. Those current streams enhance the importance of bioecosystems, which include open innovation and outsourced manufacturing for companies along with the funding supports for startups. The government of Japan has released the Bioeconomy Strategy in 2019, concentrating on the formation of bioecosystems, and Japanese academia, local governments and bioindustries are now extensively working with this strategy.

In light of this circumstances, we have planned this session to introduce current situation of bioecosystems in Japan and leading three Japanese companies, global pharmaceutical company, CDMO and VC, aggressive especially in collaborating with Taiwan bioindustry players, and will have their presentations about their strategies and plans for the collaboration or investment.

We hope that this session will help you accelerate collaborations with Japanese companies.

Date / Time:Thursday, July 27, 2023 ｜ 14:00–15:20 pm (Taipei Time)

Venue:Room 404, 4F, TaiNEX 1 (南港展覽館一館，4樓404會議室)

Co-organizer: Japan Bioindustry Association

Session Chairs: Prof. Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association

Language: English

Registration: https://forms.gle/cEDJYd5pGkhFphbN9

Agenda

14:00 - 14:05	Opening Remarks Prof. Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association
14:05 - 14:15	Bioecosystems in Japan Prof. Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association
14:15 - 14:30	Investment Strategy Leveraging Taiwan-Japan Collaboration Shuntaro Kodama, Managing Director, DCI Partners Co., Ltd.
14:30 - 14:45	Pharmaceutical Business at Otsuka Group Tetsuya Hashimoto, Ph.D., Senior Manager, Business Development Department, Otsuka Holdings Co., Ltd.
14:45 - 15:00	AGC Biologics, End-to-end CDMO Services to Bring New Protein-based Biologics and Cell & Gene Therapy to Market Ayako Kashima, Director, Business Development, Taiwan & Japan, AGC Biologics
15:00 - 15:20	Panel Discussion Moderator: Prof. Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association Panelists: Shuntaro Kodama, Managing Director, DCI Partners Co., Ltd. Tetsuya Hashimoto, Ph.D., Senior Manager, Business Development Department, Otsuka Holdings Co., Ltd. Ayako Kashima, Director, Business Development, Taiwan & Japan, AGC Biologics

Choose Malaysia – Your One-Stop Sourcing Partner

Malaysia is a strong contributor in providing essential solutions to the global life-sciences and medical technology industry, which is gaining traction in a post-pandemic world. Malaysia is committed to improving healthcare delivery standards to provide world-class medical products and technologies. The session showcases insights of Malaysia’s capabilities in areas related to the medical devices, pharmaceutical and biotechnology industries.

Date / Time:Thursday, July 27, 2023 ｜ 13:30–17:00 pm (Taipei Time)

Venue:Room 402C, 4F, TaiNEX 1 (南港展覽館一館，4樓402C會議室)

Hosted by: Malaysian Friendship and Trade Centre, Taipei
Organized by: Malaysian Friendship and Trade Centre, Taipei (Trade Division)
Supported by: Biotechnology & Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs

Language: English

Registration: https://forms.gle/cEDJYd5pGkhFphbN9

Agenda

13:30-14:00	Registration
14:00-14:05	Welcoming Remarks Madam Aznifah Isnariah Abdul Ghani, President Malaysian Friendship and Trade Centre (MFTC)
14:05-14:10	Special Remarks Dr. C.H. Herbert Wu, Director Biotechnology & Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs
14:10-14:15	Photo Session
14:15-14:40	“Malaysia’s Capabilities in Life Sciences Related Industry” Ms. Aninawati Saleh, Director of Trade Malaysian Friendship and Trade Centre (Trade Division) Our mission to promote Malaysia’s export has enabled many local companies to carve new frontiers in global markets. Today as we continue to put the spotlight on capable Malaysian companies on the international stage,we are helping make the phrase ‘Made-In Malaysia’ synonymous with excellence, reliability and trustworthiness.
14:40-15:05	“Malaysia, a reliable sourcing partner” Company Presentation 1 IDS Medical Systems (Hong Kong) Co., Ltd. - Taiwan Branch Mr. Jason Hsu, General Manager The IDS Medical Systems Group (“idsMED Group”) is a leading integrated medical supply chain solutions company in Asia for almost a decade. It represents over 200 global medical brands in equipment and medical consumables, focusing on various specialty divisions including Intensive Care, Infection Control, Surgical Workplace, Diagnostic Imaging, Patient Support System, Cardiovascular, O&G and Peri-natal, among others. IdsMED is the sole agent of Hartalega in Taiwan, one of the world's leading nitrile glove producer, with a growing capacity to manufacture billions of gloves every year.
15:05-15:30	“Choose Malaysia: World Class & Reliable” Company Presentation 2 Nova Pharma Solutions Berhad Mr. Khoo Boo Wie, CEO & Executive Director Nova Pharma Solutions Berhad specializes in delivering comprehensive engineering solutions for the pharmaceutical and biotechnology industries. Our expertise covers the entire project lifecycle, encompassing pre-design, design, post-design, and various supporting activities. We have successfully undertaken a wide range of engineering projects, including biotech, stem cell, vaccines, API & bulk, oral solid dosage, sterile & aseptic, and the nutraceutical segments.
15:30-15:55	“Choose Malaysia: World Class & Reliable” Company Presentation 3 Hovid Berhad Mr. David Ho, Managing Director Hovid Berhad, formerly known as Ho Yan Hor, carries with her years of invaluable experience in the pharmaceutical industry. Let’s have a quick look at how Hovid grew to become one of Malaysia's leading pharmaceutical manufacturers of high quality and innovative medicinal preparations and health supplements with more than 400 products distributed over 50 countries globally.
15:55-16:10	Q&A Session
16:10 – 17:00	Networking Session / End of Program

臺澳臨床試驗與生技合作論壇

澳洲辦事處與衛生福利部及經濟部於今年五月共同發表「臺澳衛生與生技合作夥伴關係」以肯定澳臺在衛生、醫療與生技領域極具成效的合作關係，包括臨床試驗、生技創新、精準醫療等領域。

今年的亞洲生計大會，澳洲辦事處、台灣生物產業協會與經濟部生技醫藥產業發展推動小組共同邀請您參加7月28日舉辦的【臺澳臨床試驗與生技合作論壇】，協助您了解更多澳洲臨床試驗產業優勢和台灣生技創新合作機會。

這次論壇共有12家澳洲臨床試驗相關的服務公司及2家創新生技公司參加。臺方則有5家生技醫藥公司。

活動日期: 2023年7月28 日 (星期五)

報到時間: 08:30-09:00 報到

活動時間: 09:00-11:50 論壇

11:50-13:30 餐敘

13:30-16:30 一對一商談會

活動地點: 南港展覽館一館402C會議室 (台北市南港區經貿二路1號)

Co-Organized by: Austrade Taiwan, BPIPO, Taiwan Bio Industry Organization

Language: English

Registration: https://forms.gle/eUZbuPUR7BujLr8D6

報名截止: 7月21日

Agenda

08:30-09:00	Registration 報到
09:00-09:10	Welcome Remarks 致歡迎詞 Representative, Australian Office 澳洲辦事處代表
09:00-09:10	Opening Remarks 致開幕詞 Dr Chung-Hsiun Wu Director, Biotechnology and Pharmaceutical Industries Promotion Office, MOEA Chairman, Taiwan Bio Industry Organisation 吳忠勳博士 / 經濟部生技醫藥產業發展推動小組主任台灣生物產業發展協會理事長
09:10-09:20	Australia - A powerhouse for science and innovation in biotechnology 澳洲：生技研究及創新大國
Part 1 - Australia’s Clinical Trials Capabilities 澳洲臨床試驗產業介紹
09:20-09:25	Pitch 1 - CSI Medical Research
09:25-09:30	Pitch 2 - George Clinical
09:30-09:35	Pitch 3 - GreenLight Clinical
09:35-09:40	Pitch 4 - Novotech
09:40-09:45	Pitch 5 - Southern Star Research
09:45-09:55	Success Story - Irene Wang, President & CSO, Lin Bioscience
09:55-10:00	Pitch 6 - CMAX Clinical Research
10:00-10:05	Pitch 7 - Nucleus Network
10:05-10:10	Pitch 8 - Scientia Clinical Research
10:10-10:15	Pitch 9 - 360 biolabs
10:15-10:20	Pitch 10 - AcuraBIO
10:20-10:25	Pitch 11 - PCI
10:25-10:30	Pitch 12 - Acclime
10:30-10:35	Tea Break
10:35-10:50	Q&A Moderator: Dr Wallace Lin, Secretary General, Taiwan Bio Industry Organisation 主持人：林治華博士 / 台灣生物產業發展協會秘書長
10:50-11:05	Pitch 13 - Australian Government, Department of Home Affairs
Part 2 - Australia & Taiwan Innovative Biotech Companies 創新生技公司介紹
11:05-11:10	Pitch 14 - Explor Biologics
11:10-11:15	Pitch 15 - Oculus Biomed
11:15-11:20	Pitch 16 - Alar Pharmaceuticals
11:20-11:25	Pitch 17 - AltruBio
11:25-11:30	Pitch 18 - Gongwin Biopharm
11:30-11:35	Pitch 19 - MegaPro Biomedical
11:35-11:50	Q&A Moderator: Dr Wallace Lin, Secretary General, Taiwan Bio Industry Organisation 主持人：林治華博士 / 台灣生物產業發展協會秘書長
11:50-13:30	Networking Luncheon
13:30-16:30	One-on-One Meetings

Taiwan Session

Date / Time: Friday, July 28, 2023 13:30-16:00

Venue: Room 404, 4F, Taipei Nangang Exhibition Center, Hall 1 (TaiNEX1) (南港展覽館一館4樓404會議室)

Registration: https://forms.gle/cEDJYd5pGkhFphbN9

Agenda

13:30-14:00	Registration
14:00-14:03	Opening Remarks Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
14:03-14:15	Taiwan’s Key Role in Building Successful Asian Biotech Ventures Sonia Chen, Deputy Director, Biotechnology and Pharmaceutical Industries Promotion Office, MOEA
14:15-14:35	Innovation, Safety, Transparency: Supporting the Biomedical Sector Through Regulatory Clarity Shou-Mei Wu, Director General, Taiwan Food and Drug Administration
14:35-14:45	Taiwan Capital Markets: Fueling the Growth of Biotech at Home and Abroad Peter Chng, Assistant Manager, Taiwan Stock Exchange
14:45-14:55	Maneuver Along the IPO Pathway Patrick Hsu, Assurance Leader, PricewaterhouseCoopers, Taiwan
14:55-15:05	M&A Trends in the Health Industries Lily Wong, Partner/Managing Director, PricewaterhouseCoopers Financial Advisory Services Co., Ltd.
15:05-16:10	Panel Discussion Moderator: Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization Panelists l Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals & Bora Biologics l Kuan-Hung Lin, Partner, PwC Taiwan l Lily Wong, Partner/Managing Director, PricewaterhouseCoopers Financial Advisory Services Co., Ltd. l Andrew Lin, Chairman, TaiRx, Inc.

Hong Kong Session

Date / Time: Friday, July 28, 2023 ｜ 9:00–10:10 pm (Taipei Time)
Venue: Room 404, 4F, TaiNEX 1
Co-organizer: Hong Kong Biotechnology Organization
Language: English
Registration: ttps://forms.gle/cEDJYd5pGkhFphbN9

Agenda

09:00–09:05	Opening Remarks Cheung Hoi (Albert) Yu, Chairman, Hong Kong Biotechnology Organization; Hai Kang Life Corporation Limited
09:05–09:20	Driving Hong Kong to become an International Innovation and Technology Hub Cheung Hoi (Albert) Yu, Chairman, Hong Kong Biotechnology Organization; Hai Kang Life Corporation Limited
09:20–09:35	Integrating Hong Kong Startups with Great Bay Area New Opportunities: The Budding Story of a Biotech Startup Focusing on Cell-Elementomics Winnie Shum, Founder, CSO, Principal Investigator, Elementomic Analytics & Diagnostics (HK) Ltd
09:35–09:50	Smart Medical Monitoring Technology Qi Lang, Principal Engineer, AP Infosense Limited
09:50–10:05	To Guardian Life and Health Ming Tang, Chief Executive Officer, Ban Loong Holding Limited
10:05–10:10	Closing Remarks Cheung Hoi (Albert) Yu, Chairman, Hong Kong Biotechnology Organization; Hai Kang Life Corporation Limited

Lithuania – your gateway to Europe

Lithuania, a small Baltic nation with a population of around 2.8 million people, has shifted its focus to Life Sciences. In this session, governmental agency responsible for attracting foreign direct investment to the country - Invest Lithuania’s, Head of Life Sciences team Karolina Karl will discuss Lithuania’s journey to becoming an independent state driven by innovation and how Life Sciences are seen as a key part of the national strategy for future economic growth. With this aim, the government set an ambitious goal to increase the GDP contribution of the Life Sciences industry from 2.5% to 5% by 2030.

To date, Lithuania has built a well-functioning business ecosystem where it takes only a few days to register a biotech company or get construction permits, all through digitalized systems aligned with EU regulations and norms. The Baltic champion also offers some of the most competitive FDI tax incentives in Europe, including one of the lowest patent box tax as well as 20 years corporate profit tax release for large scale investments. Multinational companies including Thermo Fisher, Hollister, Dexcom, Esco, Teva and others have already taken advantage of the unbeatable conditions and world-class talent pool available locally.

This session will illustrate what Lithuania can offer through stories covering the research of a local Vilnius University Professor Virginijus Siksnys, who was one of the co-founders of the CRISPR Cas9 technology, alongside Nobel Prize winners Emmanuelle Charpentier and Jennifer A. Doudna. In addition to that, you will get to know what drug was developed by Teva’s Lithuanian team and how Thermo Fisher has been growing in the market for the last 20 years.

Come and explore a new gateway to Europe!

Date / Time: On-demand

Venue:Online Event Platform

Organizer:The Lithuanian Investment Promotion Agency - Invest Lithuania, Taiwan Bio Industry Organization

Session Speaker:Mrs. Karolina Karl – Head of Life Sciences team, Invest Lithuania

Registration:https://bioasiataiwan.com/en/registration/plan

BIO Asia–Taiwan 2023 亞洲生技大會